Analysts Anticipate 27% Upside For The Holdings of VB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The Vanguard Small-Cap ETF (VB) has an implied analyst target price of $280.74, indicating a potential upside of 26.60% from its current trading price of $221.75. Notable underlying holdings with significant upside include SailPoint Inc, Bloom Energy Corp, and Adaptive Biotechnologies Corp.
Investor Considerations: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information. Investors are encouraged to conduct further research to assess the validity of these targets in light of recent developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.530
Low
20.00
Averages
20.86
High
22.00
Current: 14.530
Low
20.00
Averages
20.86
High
22.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adaptive Biotechnologies Executive Sells Shares Amid Strong Revenue Growth
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 on April 1 and 2, 2026, indicating a liquidity event amidst strong company performance.
- Ownership Analysis: The sale represents 7.85% of Rubinstein's direct holdings, leaving her with 447,202 shares post-transaction, which underscores her ongoing investment and alignment with shareholder interests.
- Financial Performance Highlights: The company reported $276.98 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment contributing over three-quarters of total sales, showcasing strong growth potential in personalized medicine.
- Profitability Outlook: While the company posted a net loss of $59.5 million, this is an improvement from $159.6 million the previous year, and management anticipates continued MRD growth in 2026, indicating progress towards broader profitability.
See More
Adaptive Biotechnologies Executive Sells Shares
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 between April 1 and 2, 2026, at an average price of $14.53 per share, indicating a liquidity need among executives.
- Holding Reduction: This transaction reduced Rubinstein's direct holdings by 7.85% to 447,202 shares, reflecting stock movements under a pre-arranged 10b5-1 plan, which may not necessarily indicate a negative outlook on the company's future.
- Performance Growth: Adaptive Biotechnologies reported $277 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment accounting for over three-quarters of total sales, growing 46% and achieving positive adjusted EBITDA, marking a significant step towards profitability.
- Future Outlook: While insider selling is often seen as a liquidity event, management anticipates continued growth in the MRD segment for 2026, prompting investors to focus on whether Adaptive can convert its strong revenue growth into sustained profitability.
See More
Adaptive Biotechnologies Executive Sells Shares Worth $1.21 Million
- Transaction Overview: Julie Rubinstein, COO of Adaptive Biotechnologies, disclosed the sale of 81,342 shares for approximately $1.21 million in an SEC Form 4 filing on March 10, 2026, reflecting executive liquidity management amid rising stock prices.
- Ownership Change Analysis: The transaction reduced Rubinstein's direct holdings by 11.22%, leaving her with 643,471 shares; despite this reduction, she retains over 510,000 vested options, maintaining a relatively stable equity exposure.
- Market Environment Impact: At the time of the sale, Adaptive Biotechnologies shares were priced around $14.90, with a 118% increase over the past year, providing a favorable backdrop for executive liquidity events, although shares have recently cooled, still up over 50% year-over-year.
- Business Outlook: Adaptive's core product, clonoSEQ, achieved 46% revenue growth in 2025 and reached profitability, with guidance for positive adjusted EBITDA and free cash flow by year-end 2026, marking a significant inflection point for a company that lost $80 million on an adjusted basis just two years prior.
See More
Adaptive Biotechnologies Executive Sells Shares
- Share Reduction Details: Julie Rubinstein, COO of Adaptive Biotechnologies, sold 81,342 shares of common stock for approximately $1.21 million between March 6 and 10, 2026, representing an 11.22% reduction in her direct holdings, which now stand at 643,471 shares, indicating a cautious outlook from the executive regarding the company's future.
- Transaction Context: The sale was executed under a pre-established 10b5-1 trading plan, involving the exercise of 68,328 stock options, with all shares being directly held and no indirect or trust-linked shares involved, reflecting the transaction's transparency and compliance.
- Market Performance and Financial Impact: According to the SEC Form 4 filing, the weighted average sale price was $14.90, while the market close on March 10, 2026, was $14.52, indicating a slight decline in market perception of the stock, which may affect investor confidence.
- Company Business Outlook: Adaptive's core product, clonoSEQ, achieved a 46% revenue growth in 2025 and reached profitability, with expectations of positive adjusted EBITDA and free cash flow by the end of 2026, marking a significant turnaround for a company that reported an $80 million loss just two years prior.
See More
Adaptive Biotechnologies Executive Sells 179,703 Shares
- Share Reduction Details: Julie Rubinstein, president and COO of Adaptive Biotechnologies, sold 179,703 shares of common stock between March 11 and March 13, 2026, for approximately $2.4 million, reducing her direct holdings to 507,934 shares, indicating a strategic adjustment in executive ownership structure.
- Transaction Context: This sale was executed under a pre-established Rule 10b5-1 trading plan as a routine stock option exercise, with the shares sold used to cover tax obligations related to RSU vesting, suggesting that this action should not be interpreted as a negative outlook on the company.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in revenue for the fiscal year 2025, a 55% year-over-year increase, with the MRD business driving most of the growth, and the company achieving positive adjusted EBITDA and cash flow, reflecting strong operational momentum.
- Market Outlook: Although the company remains unprofitable on a GAAP basis, with losses narrowing to $59.5 million, sustained growth in the MRD segment and scaling of its immune medicine platform could indicate that the recent stock price rally has further room to grow, making it a point of interest for investors.
See More
Adaptive Biotechnologies Executive Sells 179,703 Shares for $2.37 Million
- Executive Stock Sale: Julie Rubinstein, the president and COO of Adaptive Biotechnologies, sold 179,703 shares of common stock between March 11 and March 13, 2026, for approximately $2.37 million at a weighted average price of around $13.21 per share, indicating a strategic liquidity management by the executive.
- Tax Obligation Coverage: The sale was executed to cover tax withholding related to RSU vesting under a prearranged Rule 10b5-1 plan, suggesting that this transaction should not be interpreted as a negative outlook on the company's performance but rather as a standard compensation mechanism.
- Company Performance Growth: Adaptive Biotechnologies reported full-year 2025 revenue of $277 million, a 55% year-over-year increase, with its MRD business driving most of the growth, highlighting strong operational momentum and market demand in the biotechnology sector.
- Market Performance Analysis: Although the company remains unprofitable on a GAAP basis, losses narrowed significantly to about $59.5 million, and the stock price has surged over 70% in the past year, reflecting market confidence in its growth potential, particularly in scaling its immune medicine platform.
See More
Adaptive Biotechnologies Executive Sells Shares Amid Strong Revenue Growth
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 on April 1 and 2, 2026, indicating a liquidity event amidst strong company performance.
- Ownership Analysis: The sale represents 7.85% of Rubinstein's direct holdings, leaving her with 447,202 shares post-transaction, which underscores her ongoing investment and alignment with shareholder interests.
- Financial Performance Highlights: The company reported $276.98 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment contributing over three-quarters of total sales, showcasing strong growth potential in personalized medicine.
- Profitability Outlook: While the company posted a net loss of $59.5 million, this is an improvement from $159.6 million the previous year, and management anticipates continued MRD growth in 2026, indicating progress towards broader profitability.
See More
Adaptive Biotechnologies Executive Sells Shares
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 between April 1 and 2, 2026, at an average price of $14.53 per share, indicating a liquidity need among executives.
- Holding Reduction: This transaction reduced Rubinstein's direct holdings by 7.85% to 447,202 shares, reflecting stock movements under a pre-arranged 10b5-1 plan, which may not necessarily indicate a negative outlook on the company's future.
- Performance Growth: Adaptive Biotechnologies reported $277 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment accounting for over three-quarters of total sales, growing 46% and achieving positive adjusted EBITDA, marking a significant step towards profitability.
- Future Outlook: While insider selling is often seen as a liquidity event, management anticipates continued growth in the MRD segment for 2026, prompting investors to focus on whether Adaptive can convert its strong revenue growth into sustained profitability.
See More
Adaptive Biotechnologies Executive Sells Shares Worth $1.21 Million
- Transaction Overview: Julie Rubinstein, COO of Adaptive Biotechnologies, disclosed the sale of 81,342 shares for approximately $1.21 million in an SEC Form 4 filing on March 10, 2026, reflecting executive liquidity management amid rising stock prices.
- Ownership Change Analysis: The transaction reduced Rubinstein's direct holdings by 11.22%, leaving her with 643,471 shares; despite this reduction, she retains over 510,000 vested options, maintaining a relatively stable equity exposure.
- Market Environment Impact: At the time of the sale, Adaptive Biotechnologies shares were priced around $14.90, with a 118% increase over the past year, providing a favorable backdrop for executive liquidity events, although shares have recently cooled, still up over 50% year-over-year.
- Business Outlook: Adaptive's core product, clonoSEQ, achieved 46% revenue growth in 2025 and reached profitability, with guidance for positive adjusted EBITDA and free cash flow by year-end 2026, marking a significant inflection point for a company that lost $80 million on an adjusted basis just two years prior.
See More
Adaptive Biotechnologies Executive Sells Shares
- Share Reduction Details: Julie Rubinstein, COO of Adaptive Biotechnologies, sold 81,342 shares of common stock for approximately $1.21 million between March 6 and 10, 2026, representing an 11.22% reduction in her direct holdings, which now stand at 643,471 shares, indicating a cautious outlook from the executive regarding the company's future.
- Transaction Context: The sale was executed under a pre-established 10b5-1 trading plan, involving the exercise of 68,328 stock options, with all shares being directly held and no indirect or trust-linked shares involved, reflecting the transaction's transparency and compliance.
- Market Performance and Financial Impact: According to the SEC Form 4 filing, the weighted average sale price was $14.90, while the market close on March 10, 2026, was $14.52, indicating a slight decline in market perception of the stock, which may affect investor confidence.
- Company Business Outlook: Adaptive's core product, clonoSEQ, achieved a 46% revenue growth in 2025 and reached profitability, with expectations of positive adjusted EBITDA and free cash flow by the end of 2026, marking a significant turnaround for a company that reported an $80 million loss just two years prior.
See More
Adaptive Biotechnologies Executive Sells 179,703 Shares
- Share Reduction Details: Julie Rubinstein, president and COO of Adaptive Biotechnologies, sold 179,703 shares of common stock between March 11 and March 13, 2026, for approximately $2.4 million, reducing her direct holdings to 507,934 shares, indicating a strategic adjustment in executive ownership structure.
- Transaction Context: This sale was executed under a pre-established Rule 10b5-1 trading plan as a routine stock option exercise, with the shares sold used to cover tax obligations related to RSU vesting, suggesting that this action should not be interpreted as a negative outlook on the company.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in revenue for the fiscal year 2025, a 55% year-over-year increase, with the MRD business driving most of the growth, and the company achieving positive adjusted EBITDA and cash flow, reflecting strong operational momentum.
- Market Outlook: Although the company remains unprofitable on a GAAP basis, with losses narrowing to $59.5 million, sustained growth in the MRD segment and scaling of its immune medicine platform could indicate that the recent stock price rally has further room to grow, making it a point of interest for investors.
See More
Adaptive Biotechnologies Executive Sells 179,703 Shares for $2.37 Million
- Executive Stock Sale: Julie Rubinstein, the president and COO of Adaptive Biotechnologies, sold 179,703 shares of common stock between March 11 and March 13, 2026, for approximately $2.37 million at a weighted average price of around $13.21 per share, indicating a strategic liquidity management by the executive.
- Tax Obligation Coverage: The sale was executed to cover tax withholding related to RSU vesting under a prearranged Rule 10b5-1 plan, suggesting that this transaction should not be interpreted as a negative outlook on the company's performance but rather as a standard compensation mechanism.
- Company Performance Growth: Adaptive Biotechnologies reported full-year 2025 revenue of $277 million, a 55% year-over-year increase, with its MRD business driving most of the growth, highlighting strong operational momentum and market demand in the biotechnology sector.
- Market Performance Analysis: Although the company remains unprofitable on a GAAP basis, losses narrowed significantly to about $59.5 million, and the stock price has surged over 70% in the past year, reflecting market confidence in its growth potential, particularly in scaling its immune medicine platform.
See More
